首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
首頁 > 市場調查報告書 > 製藥 > 處方藥 > Medicare 處方箋藥給付制度的期中報告
產業/市場分類
製藥 (4495)
肥胖症治療 (48)
非專利藥 (117)
疫苗 (168)
神經疾病 (175)
骨頭疾病治療 (41)
動物用醫藥 (18)
處方藥 (89)
規章 (107)
感染疾病 (318)
精神病 (80)
製藥企業 (506)
糖尿病 (157)
癌症 (838)
藥物開發 (1275)
DDS (173)
OTC 非處方藥 (147)
市場調查報告書

Medicare 處方箋藥給付制度的期中報告

Progress Report on the Medicare Prescription Drug Benefit

出版商 Decision Resources, Inc.
出版日期 2005年12月 商品編碼 38504
內容資訊 英文 Pages: 17
價格
本報告書已不再販售

本報告已在2011年07月19日停止出版。

簡介

2003 年 The Medicare Prescription Drug, Improvement, and Modernization Act(一般大家知道的 MMA, Medicare Modernization Act )可謂近年來美國醫療政策的一大進展。

專門於醫療產業相關廣泛調查的美國市調公司 Decision Resources Inc. (總公司:麻薩諸塞州),針對 Medicare 處方箋藥給付制度進行調查分析,經系統整理後出版報告書 "Progress Report on the Medicare Prescription Drug Benefit" 。

本報告書內容包括: Medicare 計畫的進展與新藥劑給付制度的特徵、雇主的反應、 Medicare 藥劑給付制度對受益者、雇主、政府、 製藥產業等主要利害關係者的影響與今後趨勢。共計 17 的內容綱要摘記如下:

簡介

Medicare 的進展

Medicare 的處方箋藥給付

  • 受益者負擔費用與利益
  • 處方箋設計

雇主對 Medicare 藥劑給付制度的反應

加入 Medicare Part D

處方箋藥計畫設計

  • 國立處方箋藥計畫組織
  • 獨立處方箋藥計畫
  • 伴隨 Medicare Part D 處方箋藥給付計畫之 Medicare 的最新計畫

對利害關係人的影響

  • Medicare 受益者
  • 雇主
  • 處方箋藥計畫組織
  • 藥品產業
  • 政府

目錄

Abstract

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (commonly known as the Medicare Modernization Act, or MMA) is arguably the most significant development in U.S. health care policy in recent years. The dominant feature of the MMA is a major new prescription drug benefit that is scheduled to take effect on January 1, 2006. The U.S. health care system has spent much of 2005 gearing up for the launch of this benefit; in this report, we examine progress to date. We begin with a review of the evolution of the Medicare program and an overview of the key features of the new prescription drug benefit. We then consider employers' responses to Medicare drug coverage and enrollment in Medicare prescription drug plans. We also analyze the prescription drug plan designs of the three main types of providers-national prescription drug plan organizations (PDPOs), stand-alone plans, and Medicare Advantage drug plans. We conclude with an assessment of the outlook and implications for the main stakeholders in the Medicare drug benefit: Medicare beneficiaries, employers, prescription drug plans, government, and the pharmaceutical industry.

Table of Contents

Overview Evolution of Medicare

Medicare Prescription Drug Benefit

  • Beneficiary Costs and Benefits
  • Formulary Design

Employers' Response to the Medicare Drug Benefit

Enrollment in Medicare Part D

Prescription Drug Plan Designs

  • National Prescription Drug Plan Organizations
  • Stand-Alone Prescription Drug Plans
  • Medicare Advantage Plans with Medicare Part D Prescription Drug Benefit

Outlook and Implications for Stakeholders

  • Medicare Beneficiaries
  • Employers
  • Prescription Drug Plan Organizations
  • Pharmaceutical Industry
  • Government
Back to Top